Identification

Summary

Tiaprofenic acid is a nonsteroidal anti-inflammatory (NSAID) used to manage inflammation and analgesia associated with rheumatoid arthritis and osteoarthritis.

Generic Name
Tiaprofenic acid
DrugBank Accession Number
DB01600
Background

Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the arylpropionic acid (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 260.308
Monoisotopic: 260.05071494
Chemical Formula
C14H12O3S
Synonyms
  • 2-(5-Benzoyl-thiophen-2-yl)-propionic acid
  • 2-(5-Benzyl-2-thienyl)propionsäure
  • 5-benzoyl-α-methyl-2-thiopheneacetic acid
  • 5-benzoyl-α-methylthiophene-2-acetic acid
  • Acide tiaprofenique
  • Acido tiaprofenico
  • Acidum tiaprofenicum
  • Tiaprofenic acid
  • Tiaprofensäure
  • α-methyl-5-benzoyl-2-thienylacetic acid

Pharmacology

Indication

Tiaprofenic acid is used to treat pain, especially arthritic pain.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Tiaprofenic acid is a non-steroidal anti-inflammatory drug of the arylpropionic acid (profen) class, used to treat pain, especially arthritic pain. The typical adult dose is 300mg twice daily. This drug is not recommended for use in the pediatric population.

Mechanism of action

Tiaprofenic acid belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs). It works by blocking the production of a chemical (prostaglandin) which the body produces in response to injury or certain diseases. This prostaglandin would otherwise go on to cause swelling, pain and inflammation.

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Humans
AProstaglandin G/H synthase 2
inhibitor
Humans
Absorption

Bioavailability is 90% following oral administration.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic (10%). Sparingly metabolised in the liver to two inactive metabolites.

Route of elimination

Not Available

Half-life

1.5-2.5 hours

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
PathwayCategory
Tiaprofenic Acid Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirTiaprofenic acid may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Abciximab.
AcebutololTiaprofenic acid may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Aceclofenac.
AcemetacinThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Acenocoumarol.
AcetaminophenThe risk or severity of adverse effects can be increased when Acetaminophen is combined with Tiaprofenic acid.
AcetohexamideThe protein binding of Acetohexamide can be decreased when combined with Tiaprofenic acid.
Acetylsalicylic acidThe therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Tiaprofenic acid.
AclidiniumTiaprofenic acid may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid alcohol.
  • Take with food.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Surgamyl
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Albert Tiafen SRCapsule, extended release300 mgOralAventis Pharma Ltd.Not applicableNot applicableCanada flag
Albert Tiafen Tab 200mgTablet200 mgOralAventis Pharma Ltd.1991-12-312004-07-30Canada flag
Albert Tiafen Tab 300mgTablet300 mgOralAventis Pharma Ltd.1991-12-312004-07-30Canada flag
SurgamTablet300 mgOralSanofi Aventis1997-08-202007-11-22Canada flag
Surgam SRCapsule, extended release300 mgOralSanofi Aventis1997-02-212007-07-31Canada flag
Surgam SR Cap 300mgCapsule, extended release300 mg / capOralHoechst Roussel Canada Inc.1990-12-311999-08-11Canada flag
Surgam Tab 200mgTablet200 mg / tabOralRoussel Canada Inc.1986-12-311997-08-05Canada flag
Surgam Tab 200mgTablet200 mg / tabOralHoechst Roussel Canada Inc.1996-12-312001-07-20Canada flag
Surgam Tab 300mgTablet300 mg / tabOralHoechst Roussel Canada Inc.1995-12-311999-08-11Canada flag
Surgam Tab 300mgTablet300 mg / tabOralRoussel Canada Inc.1986-12-311997-08-05Canada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-tiaprofenic Tablets -300mgTablet300 mgOralApotex Corporation1994-12-31Not applicableCanada flag
Apo-tiaprofenic Tablets-200mgTablet200 mgOralApotex Corporation1994-12-31Not applicableCanada flag
Dom-tiaprofenicTablet200 mg / tabOralDominion PharmacalNot applicableNot applicableCanada flag
Dom-tiaprofenicTablet300 mgOralDominion Pharmacal2000-06-20Not applicableCanada flag
Nu-tiaprofenic - Tab 200mgTablet200 mgOralNu Pharm Inc1995-12-312012-09-04Canada flag
Nu-tiaprofenic - Tab 300mgTablet300 mgOralNu Pharm Inc1995-12-312012-09-04Canada flag
Penta-tiaprofenic TabletsTablet300 mg / tabOralPentapharm Ltd.Not applicableNot applicableCanada flag
Penta-tiaprofenic TabletsTablet200 mg / tabOralPentapharm Ltd.Not applicableNot applicableCanada flag
PMS-tiaprofenicTablet300 mgOralPharmascience Inc1997-07-08Not applicableCanada flag
PMS-tiaprofenicTablet200 mgOralPharmascience Inc1999-01-24Not applicableCanada flag

Categories

ATC Codes
M01AE11 — Tiaprofenic acid
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aryl-phenylketones. These are aromatic compounds containing a ketone substituted by one aryl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Aryl-phenylketones
Alternative Parents
Thiophene carboxylic acids and derivatives / Benzoyl derivatives / 2,5-disubstituted thiophenes / Heteroaromatic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives
Substituents
2,5-disubstituted thiophene / Aromatic heteromonocyclic compound / Aryl-phenylketone / Benzenoid / Benzoyl / Carboxylic acid / Carboxylic acid derivative / Heteroaromatic compound / Hydrocarbon derivative / Monocarboxylic acid or derivatives
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid, thiophenes, aromatic ketone (CHEBI:32221)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
1LS1T6R34C
CAS number
33005-95-7
InChI Key
GUHPRPJDBZHYCJ-UHFFFAOYSA-N
InChI
InChI=1S/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)
IUPAC Name
2-(5-benzoylthiophen-2-yl)propanoic acid
SMILES
CC(C(O)=O)C1=CC=C(S1)C(=O)C1=CC=CC=C1

References

General References
Not Available
Human Metabolome Database
HMDB0015538
PubChem Compound
5468
PubChem Substance
46504590
ChemSpider
5269
BindingDB
223313
RxNav
38253
ChEBI
32221
ChEMBL
CHEMBL365795
Therapeutic Targets Database
DAP000973
PharmGKB
PA164764503
Wikipedia
Tiaprofenic_acid

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentOsteoarthritis of the Knee1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Suppository
TabletOral
TabletOral200 mg
Capsule, extended releaseOral300 mg
TabletOral200 mg / tab
TabletOral300 mg / tab
Capsule, extended releaseOral300 mg / cap
Granule, for solutionOral300 MG
Injection, powder, for solutionIntramuscular200 MG/3ML
Suppository300 MG
TabletOral300 mg
Granule
Prices
Unit descriptionCostUnit
Apo-Tiaprofenic 300 mg Tablet0.43USD tablet
Novo-Tiaprofenic 300 mg Tablet0.43USD tablet
Nu-Tiaprofenic 300 mg Tablet0.43USD tablet
Apo-Tiaprofenic 200 mg Tablet0.36USD tablet
Novo-Tiaprofenic 200 mg Tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)96 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.0324 mg/mLALOGPS
logP3.22ALOGPS
logP3.66ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)4.03ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area54.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.19 m3·mol-1ChemAxon
Polarizability26.78 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9927
Blood Brain Barrier+0.9289
Caco-2 permeable+0.6039
P-glycoprotein substrateNon-substrate0.7298
P-glycoprotein inhibitor INon-inhibitor0.9534
P-glycoprotein inhibitor IINon-inhibitor0.9664
Renal organic cation transporterNon-inhibitor0.8998
CYP450 2C9 substrateNon-substrate0.6293
CYP450 2D6 substrateNon-substrate0.9226
CYP450 3A4 substrateNon-substrate0.8098
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.8607
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.8958
CYP450 3A4 inhibitorNon-inhibitor0.9526
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.9398
CarcinogenicityNon-carcinogens0.7568
BiodegradationReady biodegradable0.7714
Rat acute toxicity3.1892 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9869
hERG inhibition (predictor II)Non-inhibitor0.9716
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a5i-3910000000-04c8e1561815c7f17b73

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res. 2003 Jun 15;110(5-6):281-6. [Article]
  2. Gupta K, Kaub CJ, Carey KN, Casillas EG, Selinsky BS, Loll PJ: Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2004 Feb 9;14(3):667-71. [Article]
  3. Martic M, Tatic I, Markovic S, Kujundzic N, Kostrun S: Synthesis, biological activity and molecular modeling studies of novel COX-1 inhibitors. Eur J Med Chem. 2004 Feb;39(2):141-51. [Article]
  4. Hillarp A: [Acetylsalicylic acid resistance--clinical diagnosis with unclear mechanism]. Lakartidningen. 2004 Nov 4;101(45):3504-6, 3508-9. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Brandt KD, Albrecht ME, Kalasinski LA: Effects of tiaprofenic acid on the concentration and metabolism of proteoglycans in normal and degenerating canine articular cartilage. J Clin Pharmacol. 1990 Sep;30(9):808-14. [Article]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Drug created at August 29, 2007 18:44 / Updated at June 26, 2022 10:21